Skip to main content
Retour
QURE logo

uniQure N.V.

Qualité des données : 100%
QURE
NASDAQ Healthcare Biotechnology
15,18 €
▼ 0,74 € (-4,65%)
Cap. Boursière : 935,15M
Fourchette du Jour
15,01 € 16,10 €
Fourchette 52 Semaines
7,76 € 71,50 €
Volume
1 766 376
Moyenne 50J / 200J
20,69 € / 25,16 €
Clôture Précédente
15,92 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -4,7 0,4
P/B 4,7 2,9
ROE % -207,1 3,7
Net Margin % -1236,0 3,9
Rev Growth 5Y % -58,1 10,0
D/E 2,7 0,2

Objectif de Cours des Analystes

Hold
41,80 € +175.4%
Low: 11,00 € High: 95,00 €
BPA Prévisionnel
-3,49 €
CA Est.
32 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,52 €
0,37 € – 3,90 €
580 M 5
FY2029 -0,56 €
-1,44 € – -0,14 €
370 M 2
FY2028 -2,61 €
-4,42 € – 1,21 €
180 M 7

Points Clés

Revenue declined -58,13% annually over 5 years
Debt/Equity of 2,70 — high leverage
Negative free cash flow of -177,96M
PEG of 0,23 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 17,49%
Capital efficient — spends only 2,73% of revenue on capex

Croissance

Revenue Growth (5Y)
-58,13%
Revenue (1Y)-40,64%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-207,10%
ROIC-18,91%
Net Margin-1236,00%
Op. Margin-1152,13%

Sécurité

Debt / Equity
2,70
Current Ratio10,43
Interest Coverage-2,99

Valorisation

P/E Ratio
-4,70
P/B Ratio4,70
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -40,64% Revenue Growth (3Y) 0,80%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -58,13% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 16,10M Net Income (TTM) -198,97M
ROE -207,10% ROA -24,12%
Gross Margin -2,16% Operating Margin -1152,13%
Net Margin -1236,00% Free Cash Flow (TTM) -177,96M
ROIC -18,91% FCF Growth (3Y) N/A
Safety
Debt / Equity 2,70 Current Ratio 10,43
Interest Coverage -2,99 Dividend Yield 0,00%
Valuation
P/E Ratio -4,70 P/B Ratio 4,70
P/S Ratio 58,09 PEG Ratio 0,23
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 935,15M Enterprise Value 1,39B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 16,10M 27,12M 15,84M 106,48M 524,00M
Net Income -198,97M -239,56M -308,48M -126,79M 329,59M
EPS (Diluted) -3,46 -4,92 -6,47 -2,71 7,04
Gross Profit -347 000,0 8,79M 2,22M 103,14M 499,03M
Operating Income -185,47M -184,29M -282,87M -143,16M 310,62M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 824,91M 556,54M 831,69M 704,96M 809,18M
Total Liabilities 626,01M 563,29M 624,02M 228,96M 213,40M
Shareholders' Equity 198,90M -6,75M 207,67M 476,01M 595,78M
Total Debt 536,59M 66,06M 138,41M 142,89M 135,72M
Cash & Equivalents 80,24M 158,93M 241,36M 228,01M 556,26M
Current Assets 655,99M 390,29M 651,85M 476,77M 628,24M
Current Liabilities 62,92M 40,05M 73,68M 75,92M 36,76M